Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 19, 2018 - Issue 9
Submit an article Journal homepage
524
Views
14
CrossRef citations to date
0
Altmetric
Review

Long-term management of Parkinson’s disease using levodopa combinations

Thomas MüllerDepartment of Neurology, St. Joseph Hospital Berlin-Weißensee, Berlin, GermanyCorrespondence[email protected]
View further author information
&
Jan-Dominique MöhrDepartment of Neurology, St. Joseph Hospital Berlin-Weißensee, Berlin, GermanyView further author information
Pages 1003-1011 | Received 13 Mar 2018, Accepted 29 May 2018, Published online: 18 Jun 2018

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Nbaa Masood & Joohi Jimenez-Shahed. (2023) Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs. Neuropsychiatric Disease and Treatment 19, pages 247-266.
Read now
Thomas Müller. (2020) Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson’s disease. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 403-414.
Read now
Thomas Müller, Wilfried Kuhn & Jan-Dominique Möhr. (2019) Evaluating ADS5102 (amantadine) for the treatment of Parkinson’s disease patients with dyskinesia. Expert Opinion on Pharmacotherapy 20:10, pages 1181-1187.
Read now
Thomas Müller & Jan-Dominique Möhr. (2018) Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease. Expert Opinion on Pharmacotherapy 19:18, pages 2063-2071.
Read now

Articles from other publishers (10)

Christian Ineichen, Heide Baumann-Vogel, Matthias Sitzler & Christian R. Baumann. (2023) The risk of developing motor complications with Levodopa immediate versus dual release upon treatment initiation in Parkinson’s disease. Clinical Parkinsonism & Related Disorders 9, pages 100209.
Crossref
Gabriela Canalli Kretzschmar, Adriano D. S. Targa, Sheila Coelho Soares-Lima, Priscila Ianzen dos Santos, Lais S. Rodrigues, Daniel A. Macedo, Luis Felipe Ribeiro Pinto, Marcelo M. S. Lima & Angelica Beate Winter Boldt. (2022) Folic Acid and Vitamin B12 Prevent Deleterious Effects of Rotenone on Object Novelty Recognition Memory and Kynu Expression in an Animal Model of Parkinson’s Disease. Genes 13:12, pages 2397.
Crossref
Christine Schofield, K Ray Chaudhuri, Camille Carroll, Jagdish C Sharma, Nicola Pavese, Jonathan Evans, Thomas Foltynie, Heinz Reichmann, Laura Zurowska, Patrício Soares-da-Silva & Andrew Lees. (2022) Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease. Neurodegenerative Disease Management 12:2, pages 77-91.
Crossref
Thomas Müller. (2022) GOCOVRI ® (amantadine) extended-release capsules in Parkinson's disease . Neurodegenerative Disease Management 12:1, pages 15-28.
Crossref
Shwu‐Jiuan Lin, Lily Tai, Yu‐Jie Huang, Yow‐Shieng Uang, Yih Ho, Kuang‐Yang Hsu & Li‐Hsuan Wang. (2021) Effect of catechin and commercial preparation of green tea essence on the pharmacokinetics of l ‐dopa in rabbits . Biomedical Chromatography 35:12.
Crossref
Falaq Naz & Yasir Hasan Siddique. (2020) Role of Genes and Treatments for Parkinson’s Disease. The Open Biology Journal 8:1, pages 47-65.
Crossref
De-Qi Jiang, Ming-Xing Li, Li-Lin Jiang, Xiao-Bai Chen & Xing-Wen Zhou. (2019) Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson’s disease: a meta-analysis. Aging Clinical and Experimental Research 32:5, pages 769-779.
Crossref
Thomas Müller & Hans Michael Thiede. (2019) Bound, free, and total l-dopa measurement in plasma of Parkinson’s disease patients. Journal of Neural Transmission 126:11, pages 1417-1420.
Crossref
Thomas Müller. (2019) Therapiefreiheit zwischen gesetzlichem Rahmen und Zulassungsverfahren. NeuroTransmitter 30:10, pages 16-21.
Crossref
Thomas Müller & Jan-Dominique Möhr. (2019) Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia. Drugs 79:13, pages 1367-1374.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.